(2S,3S,4R,5S,6S)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6R)-5-Amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Term ID

CHEBI:151812

Synonyms

6-deoxy-alpha-L-galacto-hexopyranosyl-(1->2)-beta-D-galacto-hexopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-gluco-hexopyranose
Fuc(a1-2)Gal(b1-4)b-GlcN
WURCS=2.0/3,3,2/[a2122h-1b_1-5_2*N][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3/a4-b1_b2-c1

Definition

References

GlyGen:G48767OG
GlyTouCan:G48767OG

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2S,3S,4R,5S,6S)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6R)-5-Amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Phenotype where environments contain (2S,3S,4R,5S,6S)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6R)-5-Amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Phenotype modified by environments containing (2S,3S,4R,5S,6S)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6R)-5-Amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Phenotype affecting (2S,3S,4R,5S,6S)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6R)-5-Amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Human Disease Model